PMID: 9183229Jun 9, 1997Paper

A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women

Archives of Internal Medicine
M DavidsonK B Drennan

Abstract

To evaluate and compare the lipid-altering effects of conjugated estrogens and pravastatin, alone and in combination, in postmenopausal women with hypercholesterolemia. This was a double-blind, randomized, placebo-controlled clinical trial with 4 parallel groups. Participants (N = 76) were randomly assigned to receive conjugated estrogens, 0.625 mg/d; pravastatin sodium, 20 mg/d; conjugated estrogens plus pravastatin; or a placebo for 16 weeks. Primary end points were changes in serum lipid parameters. Among participants treated with conjugated estrogens, levels of non-high density lipoprotein cholesterol (non-HDL-C) (13.0%) and calculated low density lipoprotein cholesterol (LDL-C) (13.5%) decreased, while levels of HDL-C (22.5%) and triglycerides (4.2%) increased. Participants in the pravastatin group achieved reductions of 23.7% and 25.4% in non-HDL-C and calculated LDL-C levels, respectively. Levels of HDL-C increased slightly (3.7%) and triglycerides decreased by 12.1%. Among participants treated with a combination of conjugated estrogens plus pravastatin, the non-HDL-C (-25.2%) and calculated LDL-C (-28.7%) responses were similar to those of the pravastatin group, and the HDL-C response (21.2%) was similar to that observe...Continue Reading

Citations

Aug 3, 2000·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·G CastañoE Alvarez
Dec 13, 2006·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Yaprak Engin-UstünAyşe Kafkasli
Mar 26, 2002·Climacteric : the Journal of the International Menopause Society·G M DarlingS R Davis
Jan 19, 2008·Climacteric : the Journal of the International Menopause Society·A-M DupuyM-L Ancelin
Mar 7, 2012·The Medical Clinics of North America·Randolph HutterJagat Narula
Jul 12, 2008·International Journal of Cardiology·Roberto AntonicelliValerio Mais
Sep 14, 1999·The American Journal of Medicine·M A Denke
Dec 29, 2000·Journal of the American Geriatrics Society·R M LeipzigR P Soriano
May 4, 2012·Journal of Pharmacy Practice·Jennifer SanteeHeather Pace
Dec 29, 2000·Menopause : the Journal of the North American Menopause Society·S R DavisB J Strauss
Jul 10, 2003·Menopause : the Journal of the North American Menopause Society·Alfred O MueckDiethelm Wallwiener
Dec 21, 2000·Current Atherosclerosis Reports·D M Herrington, K Potvin Klein
May 23, 1998·Clinical Cardiology·J Abrams
May 5, 2001·Expert Opinion on Pharmacotherapy·J P Chin-Dusting, J A Shaw
May 25, 2002·Drugs & Aging·Michael H DavidsonKate A Ingram
Nov 8, 2002·Drugs·Mohammed H Moghadasian
Jun 16, 1999·Endocrine Reviews·J V Pinkerton, R Santen

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.